PMID- 24649313
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211021
IS  - 2049-9450 (Print)
IS  - 2049-9469 (Electronic)
IS  - 2049-9450 (Linking)
VI  - 2
IP  - 1
DP  - 2014 Jan
TI  - Sorafenib in metastatic radioactive iodine-refractory differentiated thyroid 
      cancer: A pilot study.
PG  - 87-92
AB  - The incidence and mortality of thyroid cancer are on the increase worldwide and 
      the treatment options for progressive, radioactive iodine (RAI)-refractory 
      metastatic differentiated thyroid cancer (DTC) patients are currently limited. 
      Sorafenib is a multikinase inhibitor that targets several molecular signals, 
      which are believed to be involved in the pathogenesis of DTC. In this study, we 
      reported our experience with the off-label use of sorafenib in Chinese cancer 
      patients. A total of 8 patients (7 with papillary and 1 with follicular thyroid 
      cancer) were recruited in this study. The partial response (PR) rate was 50.0% 
      and 5 of the 8 patients (62.5%) achieved a durable response. The median 
      progression-free survival (PFS) and overall survival (OS) were 40.1 and 55.0 
      weeks, respectively. Lung metastases were more sensitive to sorafenib compared to 
      lymph nodes. The tumor marker response was not in accordance with the 
      radiological response, although patients with tumor marker complete response (CR) 
      exhibited a longer PFS and OS compared to those without a CR. Common adverse 
      events (AEs) included palmar-plantar erythrodysesthesia, hypertension, diarrhea, 
      weight loss and alopecia. Grade 4 AEs comprised hypocalcemia (1 patient) and 
      elevated amylase levels (1 patient). A dose reduction was required in 62.5% of 
      the patients. In conclusion, sorafenib exhibited a clinically relevant antitumor 
      activity in patients with progressive metastatic RAI-refractory DTC, although the 
      majority of the patients required a dose reduction due to intolerable toxicity.
FAU - Luo, Yang
AU  - Luo Y
AD  - Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of 
      Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China ; 
      Beijing Key Laboratory of Clinical Study on Anticancer Molecular Target Drugs, 
      Beijing 100021, P.R. China.
FAU - Shi, Yuankai
AU  - Shi Y
AD  - Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of 
      Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China ; 
      Beijing Key Laboratory of Clinical Study on Anticancer Molecular Target Drugs, 
      Beijing 100021, P.R. China.
FAU - Xing, Puyuan
AU  - Xing P
AD  - Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of 
      Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China ; 
      Beijing Key Laboratory of Clinical Study on Anticancer Molecular Target Drugs, 
      Beijing 100021, P.R. China.
FAU - Wang, Lin
AU  - Wang L
AD  - Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of 
      Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China ; 
      Beijing Key Laboratory of Clinical Study on Anticancer Molecular Target Drugs, 
      Beijing 100021, P.R. China.
FAU - Feng, Yun
AU  - Feng Y
AD  - Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of 
      Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China ; 
      Beijing Key Laboratory of Clinical Study on Anticancer Molecular Target Drugs, 
      Beijing 100021, P.R. China.
FAU - Han, Xiaohong
AU  - Han X
AD  - Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of 
      Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China ; 
      Beijing Key Laboratory of Clinical Study on Anticancer Molecular Target Drugs, 
      Beijing 100021, P.R. China.
FAU - He, Xiaohui
AU  - He X
AD  - Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of 
      Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China ; 
      Beijing Key Laboratory of Clinical Study on Anticancer Molecular Target Drugs, 
      Beijing 100021, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20131009
PL  - England
TA  - Mol Clin Oncol
JT  - Molecular and clinical oncology
JID - 101613422
PMC - PMC3916210
OTO - NOTNLM
OT  - Chinese
OT  - differentiated thyroid cancer
OT  - radioactive iodine-refractory
OT  - sorafenib
EDAT- 2014/03/22 06:00
MHDA- 2014/03/22 06:01
PMCR- 2013/10/09
CRDT- 2014/03/21 06:00
PHST- 2013/06/02 00:00 [received]
PHST- 2013/09/11 00:00 [accepted]
PHST- 2014/03/21 06:00 [entrez]
PHST- 2014/03/22 06:00 [pubmed]
PHST- 2014/03/22 06:01 [medline]
PHST- 2013/10/09 00:00 [pmc-release]
AID - mco-02-01-0087 [pii]
AID - 10.3892/mco.2013.199 [doi]
PST - ppublish
SO  - Mol Clin Oncol. 2014 Jan;2(1):87-92. doi: 10.3892/mco.2013.199. Epub 2013 Oct 9.